New York, Jan 31, 2026, 13:49 EST — Market closed.
- The Health Care Select Sector SPDR Fund (XLV) climbed 0.6% on Friday, beating the S&P 500’s 0.4% decline.
- Eli Lilly rose 1.3% following the announcement of a new U.S. factory linked to its obesity drug efforts.
- With Feb. 2 approaching, traders are focused on big pharma earnings alongside a packed schedule of FDA-related biotech developments.
Healthcare shares ended Friday stronger than the wider market following Eli Lilly’s announcement of a $3.5 billion manufacturing facility in Pennsylvania dedicated to injectable weight-loss drugs. CEO David Ricks described the new plant as “really state of the art manufacturing to last many decades to come” during a press briefing. Reuters
The calm is notable since the market has grown jittery once more. Stronger inflation numbers and uncertainty over the next Federal Reserve chair pushed investors toward defensive plays on Friday. Health care remains one of the rare large sectors able to attract buying interest when growth stocks falter.
The market is closed for the weekend, leaving the question of what will stick once liquidity returns Monday. The week of Feb. 2 is loaded with healthcare earnings reports — Pfizer and Merck report Tuesday, Eli Lilly follows on Wednesday. Traders will zero in on guidance and pipeline updates as key drivers of price moves.
Prescription numbers are heating up competition in obesity drugs. According to IQVIA data cited by an analyst, Novo Nordisk’s Wegovy pill saw over 26,000 U.S. prescriptions in its second full week on the market. Barclays analysts described the launch as “very strong” for the week ending Jan. 23. Reuters
AstraZeneca has inked a licensing deal with China’s CSPC Pharmaceutical, potentially worth up to $18.5 billion in milestones. Macquarie’s Tony Ren described the stock move as “buy the rumour, sell the news.” AstraZeneca executive Sharon Barr said the company is targeting opportunities that deliver “better tolerability and more durable responses.” Reuters
Biotech showed it can head south just as quickly. Corcept Therapeutics dropped 10.6% after the FDA issued a corrected “complete response letter,” signaling it won’t approve the application as is. The letter revealed the agency had warned Corcept against submitting the filing in the first place—a move UBS analyst Ashwani Verma called “rare for FDA to use such language.” The SPDR S&P Biotech ETF (XBI) slipped 1.6%. Reuters
Tools makers took a hit as policy risks seeped into their outlook. Thermo Fisher dropped 2.3% after predicting 2026 profits below expectations, citing headwinds from cuts in U.S. academic research funding. CEO Mark Casper told analysts the company is factoring in “a level of customer caution.” Reuters
Medtech gave a clearer signal on procedure demand. Stryker surged 4.3% after raising its full-year profit outlook. CEO Kevin Lobo noted the company heads into 2026 with “significant momentum,” but also pointed to roughly $400 million in tariff costs this year. Reuters
ResMed caught investors’ eye as questions persist about how weight-loss drugs might affect other sectors. The company topped profit forecasts, though UBS analyst David Low noted the earnings per share beat came in “short of our forecast.” CEO Mick Farrell emphasized plans to continue pouring resources into “expand[ing] global access to life-saving care.” Reuters
Insurers closed mixed, with UnitedHealth slipping 1.8%. In that healthcare segment, traders remain focused on medical cost trends, and even minor negative news can quickly spark renewed volatility.
The risk scenario is clear-cut. Drugmakers might pour in heavy spending yet still face supply chain snarls, pricing pressure from regulators, or a clinical trial flop. Biotech stocks can plunge sharply on just one FDA letter. Device makers, meanwhile, remain vulnerable to tariffs and tightened hospital budgets if the economy stalls.
Monday’s open (Feb. 2) kicks things off, but earnings will drive the next moves: Merck and Pfizer report Feb. 3, followed by Eli Lilly on Feb. 4. Investors will be watching closely for any signals on obesity-drug demand and pricing outlook for 2026, which could shape the sector’s trajectory.
